Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $1.9 million.

  • Ocular Therapeutix's Other Accumulated Expenses fell 676.4% to $1.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.9 million, marking a year-over-year decrease of 676.4%. This contributed to the annual value of $1.9 million for FY2025, which is 676.4% down from last year.
  • As of Q4 2025, Ocular Therapeutix's Other Accumulated Expenses stood at $1.9 million, which was down 676.4% from $1.9 million recorded in Q3 2025.
  • Ocular Therapeutix's Other Accumulated Expenses' 5-year high stood at $2.1 million during Q4 2024, with a 5-year trough of $699000.0 in Q1 2021.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $1.5 million (2023), whereas its average is $1.4 million.
  • In the last 5 years, Ocular Therapeutix's Other Accumulated Expenses crashed by 3557.63% in 2021 and then soared by 6158.38% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Other Accumulated Expenses (Quarter) stood at $1.1 million in 2021, then grew by 11.13% to $1.2 million in 2022, then increased by 24.19% to $1.5 million in 2023, then surged by 34.75% to $2.1 million in 2024, then decreased by 6.76% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q4 2025, $1.9 million for Q3 2025, and $1.7 million during Q2 2025.